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S U M M A R Y
Objectives: The aim of this study was to screen the non-invasive indexes correlated with liver ﬁbrosis and
establish a scoring system for the diagnosis of liver ﬁbrosis in hepatitis B patients.
Methods: Data of 34 non-invasive indexes were collected for 208 hepatitis B patients. Correlation
analysis and stepwise discriminant analysis was used to screen out indexes useful for the diagnosis of
liver ﬁbrosis. Finally, a scoring system composed of indexes screened out by stepwise discriminant
analysis was established for the assessment of liver ﬁbrosis.
Results: Twenty-one indexes correlating with liver ﬁbrosis were screened out by correlation analysis;
hyaluronic acid had the highest r-value, 0.456. A scoring system including albumin, collagen IV, and the
longitudinal diameter of the spleen was established. The areas under the receiver operating
characteristic curves (AUC) for this scoring system and the aspartate aminotransferase to platelet
ratio index (APRI) in differentiating S3–4 from S0–2 were 0.79 (95% conﬁdence interval (CI) 0.72–0.85)
and 0.27 (95% CI 0.18–0.35), respectively. With a cut-off value of <3, the presence of signiﬁcant ﬁbrosis
(S3–4) could be excluded by this scoring system with a negative predictive value of 86.1% and sensitivity
of 86.8%. With a cut-off of >6, the presence of S3–4 ﬁbrosis could be correctly identiﬁed with a positive
predictive value of 73.6% and speciﬁcity of 87.6%. Using this scoring system, 53.4% of patients could be
classiﬁed correctly and avoid liver biopsy.
Conclusions: The scoring system provides a simpler method to identify signiﬁcant ﬁbrosis (S3–4) in
chronic hepatitis B patients.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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It has been estimated that 350 million patients are infected with
the hepatitis B virus (HBV) worldwide.1 In chronic hepatitis B
patients, repeated inﬂammation of the liver is usually accompa-
nied by progressive ﬁbrosis. In patients with signiﬁcant ﬁbrosis
there may be progression to cirrhosis and uncompensated liver
diseases.
Reliable grading of liver ﬁbrosis is very important in the
management of hepatitis B. For patients with moderate and severe* Corresponding author.
E-mail address: zxzhao@21cn.com (Z.-x. Zhao).
1 Both authors contributed equally to this study.
http://dx.doi.org/10.1016/j.ijid.2014.10.030
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ﬁbrosis, antiviral treatment should be administered more actively
to prevent progression to liver ﬁbrosis.1–4 Biopsy is the gold
standard for the diagnosis of liver ﬁbrosis, but it is an invasive
method with complications that restrict its widespread use.5,6
FibroScan has been used for the assessment of liver ﬁbrosis in
recent years, with good accuracy in chronic hepatitis C patients.7
However, the equipment is expensive, and only some large
hospitals can perform the examination. Serological methods and
ultrasound are the other two important non-invasive methods for
the diagnosis of liver ﬁbrosis, but none of the single serological and
ultrasonic indexes has a good correlation with the grading of liver
ﬁbrosis.8
Some multi-index non-invasive methods such as the aspartate
aminotransferase to platelet ratio index (APRI), FibroIndex, etc.,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Serum markers, mean  SD
ALT, U/l 197.3  217.6
AST, U/l 136.2  141.2
AST/ALT ratio 0.9  0.6
Albumin, g/l 40.5  3.9
Globulin, g/l 29.9  5.3
Albumin/globulin ratio 1.4  0.3
Total bilirubin, mmol/l 32.1  54.3
Direct bilirubin, mmol/l 11.6  27.5
GGT, U/l 103.9  77.5
ALP, U/l 97.1  51.9
Total bile acid, mmol/l 44.6  72.3
Choline esterase, U/l 7082.6  423.2
Cholesterol, mmol/l 4.2  1.0
Triglyceride, mmol/l 1.2  0.6
Apolipoprotein A1, g/l 1.2  0.3
AFP, mg/l 74.5  132.7
Prothrombin time, s 14.4  2.21
PGA index 3.2  2.1
APRI 3.0  3.5
Procollagen III, mg/l 181.4  141.2
Collagen IV, mg/l 113.1  99.6
Hyaluronic acid, ng/l 199.9  206.5
Laminin, mg/l 144.2  86.7
WBC count, 109/l 5.6  1.4
RBC count, 109/l 4.7  0.6
Platelet count, 109/l 152.7  56.6
SD, standard deviation; ALT, alanine aminotransferase; AST, aspartate aminotrans-
ferase; GGT, gamma-glutamyl transferase; ALP, alkaline phosphatase; AFP, alpha
fetoprotein; PGA, prothrombin time, g-glutamyl transferase and apolipoprotein A1
index; APRI, the AST to platelet ratio index; WBC, white blood cell; RBC, red blood cell.
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the data have come from chronic hepatitis C patients; the
accuracy in chronic hepatitis B patients is unknown. A scoring
system consisting of non-invasive indexes to improve diagnostic
accuracy in hepatitis B patients is necessary for clinical use. In
this study, we screened 34 serological and ultrasound non-
invasive indexes to establish a scoring system for the diagnosis of
liver ﬁbrosis.
2. Materials and methods
All patients were recruited from the Department of Infectious
Diseases of The Third Afﬁliated Hospital of Sun Yat-sen University
between January 2004 and December 2008. All of them were
Chinese.
Inclusion criteria were age between 18 and 60 years and a
documented HBV infection of at least 6 months. Exclusion criteria
were evidence of cirrhosis by ultrasound examination, decom-
pensated liver diseases, co-infection with other hepatitis viruses,
co-infection with HIV, accompanied by other liver diseases such as
autoimmune hepatitis, alcoholic liver disease, and fatty liver
disease.
2.1. Liver biopsy
All patients had undergone a liver biopsy for pathological
diagnosis of liver ﬁbrosis and inﬂammation. The Batts–Ludwig
grading system was used to assess the liver inﬂammation and
ﬁbrosis. The stages of ﬁbrosis of the liver were as follows: stage 1,
none or mild peri-portal ﬁbrosis; stage 2, peri-portal ﬁbrosis with/
without extension and portal–portal bridging; stage 3, portal–
central bridges but no nodular formation; and stage 4, probable or
deﬁnite cirrhosis.
2.2. Non-invasive indexes
Thirty-four non-invasive indexes were collected, including the
following: alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), AST/ALT ratio, albumin, globulin, albumin/globulin
ratio, total bilirubin, direct bilirubin, gamma-glutamyl transferase
(GGT), alkaline phosphatase (ALP), total bile acid, choline esterase,
cholesterol, triglyceride, apolipoprotein A1, alpha fetoprotein
(AFP), prothrombin time, prothrombin time, g-glutamyl transfer-
ase and apolipoprotein A1 index (PGA index), APRI, procollagen III,
collagen IV, hyaluronic acid, laminin, red blood cell count (RBC),
white blood cell count (WBC), platelet count, echo of liver
parenchyma, liver surface, gall bladder wall thickness, diameter
of the splenic vein, diameter of the portal vein, longitudinal
diameter of the spleen, thickness of the spleen, and the oblique
diameter of the right lobes of the liver.
2.3. Methods
Blood routine indexes and biochemical indexes were tested
by auto-analyzer in the laboratory of The Third Afﬁliated
Hospital of Sun Yat-sen University. Procollagen III, collagen IV,
hyaluronic acid, and laminin were tested by radioimmunoassay,
with normal ranges of 57  27 ng/l for hyaluronic acid, <120 mg/l
for procollagen III, 38.22  11.88 mg/l for collagen IV, and <102 mg/l
for laminin.
Ultrasound indexes were measured by an experienced
ultrasound technician. Echo of the liver parenchyma and liver
surface were measured by grading. For parenchymal echotexture,
a ﬁne echotexture was assigned a score of 1, mildly coarse and
even echotexture a score of 2, moderately coarse but even
echotexture a score of 3, highly coarse and uneven echotexture ascore of 4, and nodular or patchy echotexture a score of 5. For the
liver surface, a smooth liver surface was assigned a score of 1, an
unsmooth surface a score of 2, and a serrated or nodular surface a
score of 3.
2.4. Statistics
SPSS version 17.0 software was used for the statistical analysis
(SPSS Inc., Chicago, IL, USA). Normally distributed data were
expressed as the mean  standard deviation. Data with skewed
distributions were expressed as the median (range). One-way
analysis of variance (ANOVA), rank sum tests, and Spearman
correlations were used to screen out indexes correlated to ﬁbrosis
stage. Stepwise discriminant analysis was used to screen out indexes
for the diagnosis of liver ﬁbrosis. The rate of correct classiﬁcation




In total, 208 chronic hepatitis B patients were enrolled in the
study and their data were collected. One hundred and ninety-eight
patients were men and 10 were women. These patients ranged in
age from 18 to 54 years, with an average age of 30 years. The total
bilirubin was <50 mmol/l and prothrombin time was <16 s for 90%
of the patients. Baseline characteristics of the patients are shown in
Table 1.
Table 2
Inﬂammation grading and ﬁbrosis staging of the patients
Inﬂammation Fibrosis
Grade (G) n Stage (S) n
0 0 0 3
1 22 1 44
2 79 2 77
3 95 3 45
4 12 4 39
Total 208 Total 208
Z.- Huang et al. / International Journal of Infectious Diseases 31 (2015) 18–2220The inﬂammation grade and ﬁbrosis stage of the patients are
shown in Table 2. Because only three patients were in S0 ﬁbrosis,
S0 was combined with S1 for analysis.
3.2. Screening out of indexes correlated to ﬁbrosis stage
Spearman correlations were used to study the correlation
between non-invasive indexes and ﬁbrosis stage. For the normally
distributed data, we also used one-way ANOVA to test if they were
correlated with ﬁbrosis stages. For non-normally distributed data
and ranked data we also used non-parametric tests to determine if
they were correlated with ﬁbrosis stages. Using these statistical
methods, 21 indexes were found to correlate with ﬁbrosis stage.
According to the r-value, ranging from large to small, they were
hyaluronic acid, albumin, direct bilirubin, AFP, PGA index, platelets,
total bilirubin, total bile acid, collagen IV, procollagen III, apolipo-
protein A1, APRI, ALP, gall bladder wall thickness, GGT, longitudinal
diameter of the spleen, RBCs, laminin, AST/ALT ratio, prothrombin
time, and diameter of the splenic vein (Table 3). The r-values of these
indexes with inﬂammation grades are also shown in Table 3.
3.3. Stepwise discriminant analysis of liver ﬁbrosis diagnosis
Stepwise discriminant analysis was used to establish discrimi-
nant function for distinguishing different stages of liver ﬁbrosis.Table 3






r p-Value r p-Value
Hyaluronic acid 0.456 <0.001 0.377 <0.001
Albumin 0.447 <0.001 0.361 <0.001
Direct bilirubin 0.418 <0.001 0.277 <0.001
AFP 0.416 <0.001 0.462 <0.001
PGA index 0.413 <0.001 0.475 <0.001
Platelets 0.382 <0.001 0.288 <0.001
Total bilirubin 0.368 <0.001 0.23 0.001
Total bile acid 0.363 <0.001 0.408 <0.001
Collagen IV 0.35 <0.001 0.28 <0.001
Procollagen III 0.326 <0.001 0.317 <0.001
Apolipoprotein A1 0.315 <0.001 0.256 <0.001
APRI 0.313 <0.001 0.391 <0.001
ALP 0.312 <0.001 0.308 <0.001
Gall bladder wall thickness 0.308 <0.001 0.287 <0.001
GGT 0.3 <0.001 0.397 <0.001
Longitudinal diameter of spleen 0.3 <0.001 0.151 0.032
RBC count 0.3 <0.001 0.146 0.035
Laminin 0.276 0.001 0.184 0.032
AST/ALT 0.272 <0.001 0.139 0.051
Prothrombin time 0.269 <0.001 0.257 <0.001
Diameter of the splenic vein 0.255 <0.001 0.136 0.053
AFP, alpha fetoprotein; PGA, prothrombin time, g-glutamyl transferase and
apolipoprotein A1 index; APRI, AST to platelet ratio index; ALP, alkaline
phosphatase; GGT, gamma-glutamyl transferase; RBC, red blood cell; AST/ALT,
aspartate aminotransferase/alanine aminotransferase ratio.Four indexes were identiﬁed as useful for distinguishing S0–1, S2,
S3 and S4: the PGA index, albumin, red blood cells, and procollagen
III. Of the study patients, 51.9% were correctly classiﬁed by the
discriminant function. Next, the adjacent stages of liver ﬁbrosis
were combined and stepwise discriminant analysis was again used
to distinguish the combined groups. Of the patients, 67.0% were
correctly classiﬁed into S0–1 and S2–3 by the discriminant
function; only the PGA index entered into the discriminant
function. Of the study patients, 83.4% were correctly classiﬁed
into S0–2 and S3–4; albumin, procollagen III, collagen IV, total bile
acid, red blood cell, AFP, AST/ALT, and the longitudinal diameter of
the spleen entered the discriminant function. Of the study patients,
80.8% were correctly classiﬁed into S0–3 and S4; the PGA index,
collagen IV, AST/ALT and longitudinal diameter of the spleen
entered the discriminant function (Table 4).
3.4. Scoring system
To distinguish the S0–2 and S3–4 groups of liver ﬁbrosis with a
more simple method, albumin, collagen IV, and the longitudinal
diameter of the spleen were chosen to establish a scoring system.
The scores of these three indexes are shown in Table 5. The areas
under the receiver operating characteristic curves (AUC) for the
scoring system and APRI in differentiating S3–4 from S0–2 were 0.79
(95% conﬁdence interval (CI) 0.72–0.85) and 0.27 (95% CI: 0.18–
0.35), respectively (Figure 1). With a cut-off value of <3, the presence
of signiﬁcant ﬁbrosis (S3–4) could be excluded by the scoring system
with a negative predictive value of 86.1% and sensitivity of 86.8%.
With a cut-off value of >5, the presence of S3–4 ﬁbrosis could be
correctly identiﬁed with a positive predictive value of 73.6% and
speciﬁcity of 87.6%. Overall, 53.4% of patients could be correctly
classiﬁed by the scoring system. The numbers of patients in the
different ranges of the scoring system and APRI are shown in Table 6.
4. Discussion
To objectively evaluate the stage of ﬁbrosis, liver biopsy,
especially a series of biopsies, is the main method currently used.
Biopsy is still the gold standard for the diagnosis of liver ﬁbrosis,
but it is an invasive method, which restricts its extensive use.5,6
Therefore, non-invasive methods are still widely used in clinical
practice. Direct serological markers of ﬁbrosis include those
associated with matrix deposition, such as procollagen type III
amino-terminal peptide (P3NP), type IV collagens, laminin, and
hyaluronic acid. These indexes are better than liver function tests
in assessing liver ﬁbrosis. However, their accuracy for diagnosing
liver ﬁbrosis is still low.8–10 Ultrasound examination often shows
ﬁndings of cirrhosis, but this modality is not particularly sensitive,
with a low negative predictive value.
Combining the non-invasive indexes could improve the overall
diagnostic coincidence rate. There are several models that combineTable 4
Bayes stepwise discriminant to distinguish different ﬁbrosis groups
Groups Rates of correct
classiﬁcation
Indexes entered – discriminant function
S0–1 and S2–4 67.0% PGA index
S0–3 and S4 80.8% PGA index, collagen IV, longitudinal diameter
of spleen, and AST/ALT
S0–2 and S3–4 83.4% Albumin, procollagen III, collagen IV,
RBC count, AFP, total bile acid, AST/ALT, and
longitudinal diameter of spleen
PGA, prothrombin time, g-glutamyl transferase and apolipoprotein A1 index; AST/
ALT, aspartate aminotransferase/alanine aminotransferase ratio; RBC, red blood
cell; AFP, alpha fetoprotein.
Table 5
Scoring system
Score Albumin, g/l Collagen IV, mg/l SPL, mm
0 45 <50 <100
1 40–45 50–100 100–110
2 35–40 100–200 110–120
3 <35 200 120
SPL, longitudinal diameter of spleen.
Table 6
Numbers of patients in the different ranges of the scoring system and APRI
Score S0–2 (n) S3–4 (n) APRI S0–2 (n) S3–4 (n)
3 62 10 <0.5 12 4
4–5 37 27 0.5–1.5 46 35
6 14 39 >1.5 57 54
APRI, aspartate aminotransferase to platelet ratio index.
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such as the AST/ALT ratio, AST to platelet ratio index (APRI), and
PGA index, the positivity and speciﬁcity are still low even after
combining the indexes.11–16 Other models such as FibroMeter,
FibroTest, FibroSure, and the sequential algorithm for ﬁbrosis
evaluation (SAFE) have shown good accuracy in detecting
signiﬁcant ﬁbrosis or cirrhosis,17–20 but the calculation of the
combined indexes is complicated, which restricts their clinical use.
Ultrasound elastography (FibroScan) is an exciting recent devel-
opment in the non-invasive measurement of hepatic ﬁbrosis. It has
shown excellent diagnostic accuracy for diagnosing cirrhosis in
hepatitis C patients.21 However, the device is expensive and only
available in some hospitals. Existing problems are the following:
non-invasive indexes alone have poor accuracy for the diagnosis of
liver ﬁbrosis; combined indexes could diagnose signiﬁcant ﬁbrosis
or cirrhosis well, but the calculation is complicated; the promising
method FibroScan is not available in many hospitals. Thus we need
a more simple scoring system to diagnose liver ﬁbrosis.
This study aimed to establish a simple scoring system for the
diagnosis of ﬁbrosis. To ensure its simplicity and widespread use,
even in small hospitals, the non-invasive indexes in our study are
all used widely in clinical practice with established test methods.
Of the 34 non-invasive indexes, none was found to have a high
correlation with the ﬁbrosis stage. The highest r-value was only
0.456. These results indicate that a single non-invasive indexFigure 1. Areas under the receiver operating characteristic curves (AUC) for the
scoring system and APRI in differentiating S3–4 from S1–2 were 0.79 (95% CI 0.72–
0.85) and 0.267 (95% CI 0.18–0.35), respectively.cannot adequately discriminate the four stages of ﬁbrosis, which is
in agreement with other studies.8 A combination of the indexes
could improve the rate of correct classiﬁcation. The more indexes
we combine in the discriminant function, the better the correct
classiﬁcation rate we can obtain, but the diagnostic model
becomes more complicated when more indexes are combined,
which restricts its use in clinical practice. The present study
showed that it is difﬁcult to discriminate the four stages even
combining non-invasive indexes. We then combined the adjacent
stages and again used Bayes stepwise discriminant analysis to
distinguish the combined groups. We obtained the highest rate of
correct classiﬁcation, 83.4%, in classifying the S0–2 and S3–4
groups of ﬁbrosis. The S0–2 group represents slight and moderate
ﬁbrosis and the S3–4 group represents signiﬁcant ﬁbrosis and early
cirrhosis. It is very important to distinguish these two ﬁbrosis
groups in clinical practice. For chronic hepatitis B patients with
signiﬁcant ﬁbrosis and early cirrhosis, prompt antiviral treatment
should be administered to prevent progression to decompensated
cirrhosis liver diseases.
Using Bayes stepwise discriminant analysis, we established a
function comprising albumin, procollagen III, collagen IV, RBC, AFP,
total bile acid, AST/ALT ratio, and longitudinal diameter of the
spleen for the diagnosis of the S0–2 and S3–4 groups of ﬁbrosis;
83.4% of the patients were correctly classiﬁed by the discriminant
function. However, the calculation of the function is complicated.
So we chose collagen IV, albumin, and longitudinal diameter of the
spleen to establish a scoring system. Procollagen III and collagen IV
are two of the direct liver ﬁbrosis indexes reﬂecting the increasing
synthesis of extracellular matrix. We chose collagen IV, with a
higher r-value of 0.35, as one of the scoring indexes. Several liver
function indexes such as albumin, total bile acid, and AST/ALT ratio
entered the discriminant function. Albumin reﬂects the synthesis
ability of the liver and has a relatively high r-value of 0.447,
which is only slightly lower than that of hyaluronic acid. Thus, we
chose it as the second scoring index. The longitudinal diameter of
the spleen is the only ultrasound index to enter the discriminant
function. The enlargement of the spleen is caused by high portal
vein pressure. The degree of ﬁbrosis is the most important factor
inﬂuencing portal vein pressure. Thus, we chose the longitudinal
diameter of spleen as the third scoring index. RBC and AFP also
entered the discriminant function. However, many factors may
inﬂuence the value of the RBC, such as hematological system
diseases. AFP is related to primary liver carcinoma and the
proliferation of liver cells. Therefore, we did not choose either RBC
or AFP as indexes for our scoring system.
Combined indexes for the diagnosis of liver ﬁbrosis have
already been reported. SAFE combines the APRI and FibroTest–
FibroSure tests in a sequential fashion to test for ﬁbrosis and
cirrhosis. In a study to detect signiﬁcant ﬁbrosis, it showed an
accuracy of 90.1%, AUC was 0.89, and it reduced 46.5% of liver
biopsies.20 Although the accuracy of SAFE in other studies has been
better than our scoring system, the calculation of SAFE is
complicated and some indexes in SAFE are not commonly used
in clinical practice. Our scoring system is simple to calculate and
has only three indexes: albumin, collagen IV, and longitudinal
diameter of the spleen. Although the diagnostic coincidence rate is
lower than that of the discriminant function consisting of eight
indexes, the scoring system is simple and applicable to clinical
Z.- Huang et al. / International Journal of Infectious Diseases 31 (2015) 18–2222procedures. Albumin, collagen IV, and the longitudinal diameter of
the spleen are common indexes used in clinical practice and can
even be performed in small hospitals. Thus, this scoring system
could be used widely for the assessment of liver ﬁbrosis. The AUC
for the scoring system in differentiating S3–4 from S0–2 was 0.79
(95% CI 0.72–0.85). Overall, 53.4% of patients could be correctly
classiﬁed and avoid liver biopsy using the scoring system.
The APRI is another simple index for assessing liver ﬁbrosis. In
studies of hepatitis C and hepatitis C–HIV, the APRI has shown a
sensitivity of 37–80% and a speciﬁcity of 45–98%.8 In our chronic
hepatitis B cohort, however, the APRI showed low precision in
identifying signiﬁcant ﬁbrosis (S3–4), with an AUC of 0.267. AST is
easily inﬂuenced by the inﬂammation grading. Hepatitis ﬂare with
elevated AST is common in chronic hepatitis B patients. In our
cohort, 51.4% of the patients were in G3–4 inﬂammation and the
average level of AST was 136.2  141.2 U/l. The high level of AST
caused by inﬂammation may be the reason why the APRI showed low
precision in chronic hepatitis patients.
In conclusion, none of the non-invasive indexes could
distinguish the four stages of liver ﬁbrosis effectively. A scoring
system comprising albumin, collagen IV, and longitudinal
diameter of the spleen provides a simple method to differentiate
S3–4 from S0–2 in chronic hepatitis B patients. Overall, 53.4% of
patients could be correctly classiﬁed and avoided liver biopsy.
This promising method to identify signiﬁcant ﬁbrosis warrants
further investigation.
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